Ignite Creation Date:
2024-05-06 @ 6:49 PM
Last Modification Date:
2024-10-26 @ 2:55 PM
Study NCT ID:
NCT05795296
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-08-30
First Post:
2023-03-21
Brief Title:
Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer
Sponsor:
RenJi Hospital
Organization:
RenJi Hospital
Study Overview
Official Title:
Clinical Study of Fruquintinib in Combination With Sintilimab as a First-line Therapy in Gastric AdenocarcinomaAdenocarcinoma of Esophagogastric Junction
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to explore the efficacy and safety in patients with gastric adenocarcinoma or adenocarcinoma of esophagogastric junction The main questions it aims to answer are
Does this therapy have a promising efficacy
Does this therapy have a manageable toxicity Participants will receive fruquintinib plus sintilimab as first-line therapy for gastric cancer
Does this therapy have a promising efficacy
Does this therapy have a manageable toxicity Participants will receive fruquintinib plus sintilimab as first-line therapy for gastric cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None